Zeidan discusses the interim results from the ongoing phase 1/2 trial, highlighting bexmarilimab’s efficacy in combination with azacitidine SoC.
Amer Zeidan, MD
Advertisement
Amer Zeidan, MD, is a professor of medicine and the chief of the Division of Hematologic Malignancies at Yale University.
Articles by Amer Zeidan, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
APPs on the Frontline of AATD Management, With Sarah Tomashefski, MSN
2
Positioning New Agents and Overcoming Real-World Barriers for Asthma and COPD
3
Phase 3 Data Indicate Roflumilast Cream Benefit Extend to Youngest Atopic Dermatitis Patients
4
RAD 2026: Tralokinumab Improves Hand AD Outcomes, Outperforms Dupilumab in MAIC
5